相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays
Edelgard Lindhoff-Last et al.
ANNALS OF MEDICINE (2013)
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation
Takahiko Tanigawa et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay
M. M. Samama
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients REPLY
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects
Dagmar Kubitza et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Joachim Stangier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
Xu Steven Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno et al.
CHEST (2012)
Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects
D. Kubitza et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin
Helen Mani et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
Dagmar Kubitza et al.
PHARMACEUTICALS (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Keith A. A. Fox et al.
EUROPEAN HEART JOURNAL (2011)
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
Kenneth Todd Moore et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure
Mihai Gheorghiade et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Elisabeth Perzborn et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
Rolf Burghaus et al.
PLOS ONE (2011)
The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants
Meyer Michel Samama
THROMBOSIS RESEARCH (2011)
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Assays for Measuring Rivaroxaban: Their Suitability and Limitations
Edelgard Lindhoff-Last et al.
THERAPEUTIC DRUG MONITORING (2010)
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
Ji Jiang et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Xia Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
C. Weinz et al.
DRUG METABOLISM AND DISPOSITION (2009)
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
J. L. Mega et al.
LANCET (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Dagmar Kubitza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation
Dagmar Kubitza et al.
DRUG SAFETY (2008)
Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
G. Rohde
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
Jochen Graff et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
G. T. Gerotziafas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
D Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939):: An oral, direct factor Xa inhibitor
S Roehrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs
C Weinz et al.
XENOBIOTICA (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
E Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
分享论文
